SalvaRx Overview

Founded 2015
Status Public
Stock Symbol SALV
Stock Symbol
Investments 4

SalvaRx General Information


Provider of drug development services intended to focus on immune-oncology therapies. The company's activities include research and development of drugs and other related pharmaceutical products, enabling pharmaceutical companies to assemble and develop a portfolio of differentiated immune-oncology therapies for the treatment of late-stage cancers.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Stock Exchange
Primary Office
  • Commerce House
  • 1 Bowring Road
  • Ramsey IM8 2LQ
  • Isle of Man, United Kingdom
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

SalvaRx Financials Summary

In Thousands,
TTM 31-Dec-2016 FY 2016 31-Dec-2016 FY 2015 31-Dec-2015
EBITDA (3,101) (3,101) (595)
Total Debt 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

SalvaRx Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore SalvaRx‘s full profile, request access.

Request a free trial

SalvaRx Executive Team (4)

Name Title Board Seat Contact Info
Ian Walters MD Co-Founder, Chief Executive Officer & Executive Director
Robert Kramer Ph.D Co-Founder & Chief Scientific Officer
Jim Mellon Non-Executive Chairman
Denham Eke Chief Financial Officer & Director

SalvaRx Board Members (1)

Name Representing Role Since
000 000000 SalvaRx Non-Executive Chairman 000 0000

SalvaRx Investments & Acquisitions (4)

To view SalvaRx‘s complete investment and acquisition history, request access >>
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 01-Jan-2018 00000 0000000 Therapeutic Devices 000 0000000 00
0000000 00000000 01-Feb-2017 00000 0000000 Biotechnology 000 0000000 00
00000 000000000 20-Mar-2016 000000000000000000 Energy Exploration
iOx Therapeutics Merger/Acquisition Drug Discovery